Cancer Vaccine Week articles from August 2008

Cancer Vaccine Week archives from August 2008

New cancer vaccines study findings have been reported from INSERM.(Report)
August 4, 2008... According to recent research from France, "Despite conventional medical and surgical treatments, malignant pleural mesothelioma (MPM) remains incurable. Oncovirotherapy (i.e., the use of replication-competent virus for cancer treatment) is...

New findings from Auburn University, Medical Department in the area of cancer vaccines published.
August 4, 2008... According to a study from the United States, "Mammary cancer is among the most prevalent of canine tumors frequently resulting in death due to metastatic disease. Most tumors fail to raise an effective immune reaction making improving immune...

Reports outline cancer vaccines research from University of Toronto.
August 4, 2008... "Reports of turner regression after infection date back as far as 1550 BC. In the twentieth century, Dr," scientists writing in the Journal of Thoracic Oncology report (see also Cancer Vaccines). "William Coley, witnessing regression of a...

Research on cancer vaccines published by scientists at Mayo Clinic, Medical Department.(Report)
August 4, 2008... "Recent studies have shown the importance of helper CD4 T cells in initiating and sustaining tumor-specific CD8 T-cell immunity. This has paved the way for identifying MHC class II epitopes that could be incorporated into class I-based...

Studies from National Cancer Institute in the area of cancer vaccines described.
August 4, 2008... According to recent research from the United States, "Hepatitis B virus (HBV) infection remains a serious global health problem despite the availability of a highly effective vaccine. Approximately 5% of HBV-infected adults develop chronic...

Brain Cancer Study: Magnitude of Post-Vaccine Immune Response Linked to Clinical Outcomes.
August 4, 2008... Researchers conducting a clinical trial of a dendritic cell vaccine designed to fight malignant brain tumors called glioblastoma multiforme (GBM) have found a correlation between the "intensity" of a patient's immune response and clinical...

USCIS Tightens Vaccination Requirements.
August 4, 2008... New vaccine requirements will affect anyone who is applying for an immigrant visa for entry into the U.S. and anyone seeking adjustment of status for permanent residence. Applicants must show proof of vaccinations against vaccine-preventable...

Data on cancer vaccines detailed by researchers at University of Texas.
August 11, 2008... According to recent research from the United States, " Treatment of localised renal cell carcinoma consists of partial or radical nephrectomy. A substantial proportion of patients are at risk for recurrence because no effective adjuvant therapy...

New findings in cancer vaccines described from Fourth Military Medical University.
August 11, 2008... "Tumor antigen-derived peptides have been widely used to elicit tumor-specific cytotoxic T lymphocytes (CTLs). MAGE gene products are of particular interest owing to their wide expression in many tumors and their potential to induce...

Recent findings from University of Texas highlight research in cancer vaccines.
August 11, 2008... According to a study from the United States, "For the current study, the authors sought to determine whether administration of multiple-dose granulocyte-macrophage-colony-stimulating factor (GM-CSF) could improve response to standard 23-valent...

Research reports on cancer vaccines from Thomas Jefferson University provide new insights.
August 11, 2008... " One of the greatest impediments to cancer immunotherapy is the paucity of antigens that are tumor specific, sufficiently immunogenic, and shared among patients. Mucosa-restricted antigens that are expressed by tumor cells represent a novel...

New measles study findings have been reported by researchers at Mayo Clinic.
August 11, 2008... "Patients recruited in virus-based cancer clinical trials and immunocompromised individuals in need of vaccination would profit from viral strains with defined attenuation mechanisms. We generated measles virus (W) strains defective for the...

NVENTA ANNOUNCES FINAL DATA FROM HSPE7 PHASE 1 CERVICAL DYSPLASIA TRIAL -- Company Provides Update to Phase 2 Development Plan.
August 11, 2008... Nventa Biopharmaceuticals Corporation (TSX:NVN) announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial for HspE7, its lead product candidate. HspE7 is a therapeutic treatment for...

Immunotherapy in high-risk pediatric sarcomas shows promising response.
August 18, 2008... Based on a pilot study in children with sarcoma, researchers at the National Institutes of Health (NIH) believe that immunotherapy could prove beneficial in treating high-risk forms of this cancer (see also American Association for Cancer...

Data from University of Nijmegen provide new insights into cancer vaccines.
August 18, 2008... According to recent research published in the journal Cancer Research, "Immunostimulatory cytidyl guanosyl (CpG) motifs are of great interest as cancer vaccine adjuvants. They act as potent inducers of Th1 responses, including the activation of...

Research on cancer vaccines detailed by scientists at Washington University, Medical Department.
August 18, 2008... " Mammaglobin-A(mam-A) is expressed in over 80% of human breast tumors. We recently reported that mam-A DNA vaccination resulted in breast cancer immunity in a preclinical model," scientists in the United States report (see also Cancer...

New findings from N. Bhatla and co-authors describe advances in human papillomavirus.
August 18, 2008... "Our objective was to determine the human papillomavirus (HPV)-type prevalence in cervical samples in women with and without cervical neoplasia in an opportunistic hospital-based cancer-screening program. A cross-sectional study of 524 Women...

Scientists at University Hospital release new data on human papillomavirus.
August 18, 2008... "In Phase II/III trials, administration of quadrivalent human papillomavirus (HPV) (types 6/11/16/18) L1 virus-like-particle vaccine was highly effective in preventing HPV-6/11/16/18-related cervical intraepithelial neoplasia and non-invasive...

Data on cancer vaccines described by investigators at University of Lausanne, Ludwig Institute for Cancer Research.
August 18, 2008... Investigators publish new data in the report 'Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.' "Expression of the cancer/germ-line antigen NY-ESO-1 by tumors elicits spontaneous humoral and cellular...

Data on cancer vaccines reported by researchers at University of California, Division of Neurosurgery.
August 18, 2008... Fresh data on cancer are presented in the report 'Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain.' "It is commonly believed that T cells have difficulty reaching tumors located in the...

Data on cancer vaccines reported by V. Shahabi and co-researchers.(Report)
August 18, 2008... Research findings, 'Development of a Listeria monocytogenes based vaccine against prostate cancer,' are discussed in a new report. According to a study from the United States, "Prostate specific antigen (PSA) is a likely immunotherapeutic...

Research on cancer vaccines detailed by scientists at Columbia University.(Report)
August 18, 2008... Data detailed in 'Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer' have been presented. "The combination of vaccines and chemotherapy holds promise for cancer therapy, but the effect of...

Research on cancer vaccines reported by scientists at Charite University, Department of Pediatrics.
August 18, 2008... Current study results from the report, 'A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity,' have been published. According to recent research published in the journal Molecular Cancer...

Scientists at National Institutes of Health detail research in cancer vaccines.
August 18, 2008... Researchers detail in 'Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers,' new data in cancer. According to recent research from the United States, "There is mounting evidence...

Scientists at School of Medicine discuss research in cancer vaccines.
August 18, 2008... New investigation results, 'Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design,' are detailed in a study...

Scientists at University of Michigan describe research in cancer vaccines.(Report)
August 18, 2008... Research findings, 'Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer,' are discussed in a new report. "A pivotal obstacle to cancer immunotherapy is peripheral T cell tolerance to...

Scientists at Kyushu University, Medical Institute of Bioregulation report research in gene therapy.(Report)
August 18, 2008... A new study, 'TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model,' is now available. "Transduction of the granulocyte-macrophage colony stimulating factor (GM-CSF) gene into mouse...

Antigenics Reports Second Quarter 2008 Financial Results.(Financial report)
August 18, 2008... Antigenics Inc. (NASDAQ: AGEN) reported results today for the quarter ended June 30, 2008. The company incurred a net loss attributable to common stockholders of $12.2 million, or $0.19 per share, basic and diluted, for the second quarter of...

AVANT Reports Second Quarter and Six Month Financial Results.(Financial report)
August 18, 2008... AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) reported financial results for the second quarter and six-month period ended June 30, 2008. AVANT reported a net loss of $10.3 million, or $0.67 per share, for the second quarter of 2008 compared to...

CORRECTING and REPLACING AVANT Reports Second Quarter and Six Month Financial Results.(Financial report)
August 18, 2008... Please replace the release with the following corrected version due to multiple revisions (see also AVANT Immunotherapeutics, Inc.). AVANT REPORTS SECOND QUARTER AND SIX MONTH FINANCIAL RESULTS Conference Call Wednesday, August 6 at...

Biovest Joins in the Formation of the Joint U.S.-Norway Cancer Research Program, a Collaborative Effort with Plans to Present to NCI and the U.S. Military Healthcare System.
August 18, 2008... Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced that Biovest has been designated one of the charter members of the Joint U.S.-Norway Cancer Research Program, a...

Cell Genesys Reports Second Quarter 2008 Financial Results.(Financial report)
August 18, 2008... Cell Genesys, Inc. (Nasdaq:CEGE) reported financial results for the second quarter ended June 30, 2008. The net loss for the quarter ended June 30, 2008, was $2.8 million ($0.03 per fully diluted share), compared to a net loss of $1.9 million...

Data on cancer vaccines detailed by researchers at Harvard University.
August 25, 2008... According to a study from the United States, "Cervical cancer is a leading cause of cancer death among women in low-income countries, with similar to 25% of cases worldwide occurring in India. We estimated the potential health and economic...

Findings from University of North Carolina provide new insights into cancer vaccines.
August 25, 2008... "We have previously described a simple yet effective liposome-based therapeutic vaccine, DOTAP/E7, which contains only two molecules, the cationic lipid DOTAP and a peptide antigen derived from the E7 oncoprotein of human papillomavirus (HPV)...

Findings in cancer vaccines reported from R. Ramlau and co-researchers.(Clinical report)
August 25, 2008... According to a study from Poznan, Poland, "TG4010 is a recombinant viral vector expressing both the tumor-associated antigen MUC1 and Interleukine-2. This vector is based on the modified virus of Ankara, a significantly attenuated strain of...

New cancer vaccines study results from Mayo Clinic, Medical Department described.
August 25, 2008... "The Edmonston vaccine strain of measles virus has potent and selective activity against a wide range of tumors. Tumor cells infected by this virus or genetically modified strains express viral proteins that allow them to fuse with neighboring...

New findings reported from University of Yamanashi describe advances in cancer vaccines.
August 25, 2008... "We recently identified three HLA-A2402-restricted epitope peptides derived from cancer-testis antigens (CTA), TTK protein kinase (TTK), lymphocyte antigen 6 complex locus K (LY6K), and insulin-like growth factor (IGF)-II mRNA binding protein 3...

Recent studies from University of Naples add new data to cancer vaccines.(Report)
August 25, 2008... According to a study from Naples, Italy, "This study assesses knowledge, attitudes, and behavioural intention towards human papillomavirus (HPV) infection and vaccination in a random sample of 1348 adolescents and young women aged 14-24 years...

Reports outline cancer vaccines study findings from University of New Mexico.
August 25, 2008... "Human chorionic gonadotropin (hCG) is a heterogeneous glycoprotein hormone comprising an alpha-subunit and beta-subunit that can vary in peptide and carbohydrate structure. After conception, hCG produced by early trophoblast cells acts on...

New melanoma study findings have been published by scientists at Melanoma Center.
August 25, 2008... According to recent research from the United States, "Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) are 2 cytokines with distinct mechanisms of action that complement one another in the adjuvant management...

Data on cancer vaccines detailed by researchers at Osaka University.(Report)
August 25, 2008... New research, 'WT1 peptide vaccine for the treatment of cancer,' is the subject of a report. According to recent research from Japan, "Wilms' tumor gene WT1 is expressed in various kinds of cancers. Human WT1-specific cytotoxic T lymphocytes...

Researchers from National Institutes of Health report on findings in cancer vaccines.(Clinical report)
August 25, 2008... Researchers detail in 'Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy,' new data in cancer. "We reported previously the first randomized...

Scientists at Technical University, University Health Science Center describe research in cancer vaccines in women.(Clinical report)
August 25, 2008... Research findings, 'Geriatric screening and preventive care,' are discussed in a new report. "Preventive health care decisions and recommendations become more complex as the population ages. The leading causes of death (i.e., heart disease,...

Researchers from Monash University detail findings in cancer vaccines immunotherapy.
August 25, 2008... A new study, 'Targeted therapies to improve tumor immunotherapy,' is now available. According to a study from Melbourne, Australia, "Durable tumor regression and potential cures of metastatic solid cancers can be achieved by a variety of...

Data on cancer vaccines therapy reported by investigators at University of Texas, Cancer Therapy & Research Center.
August 25, 2008... Fresh data on cancer vaccines are presented in the report 'Regulatory T cells and treatment of cancer.' "CD4+CD25+FOXP3+ regulatory T cells (Tregs) are elevated in cancers and can thwart protective antitumor immunity. Recent human cancer trials...

Researchers from Trinity College publish findings in immunization.
August 25, 2008... Scientists discuss in 'Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma' new findings in immunization. According to recent research from Dublin,...

Bavarian Nordic Announces Partnership With National Cancer Institute in the US and Obtains Rights to a New Vaccine Candidate.
August 25, 2008... Bavarian Nordic's US subsidiary, BN ImmunoTherapeutics has entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and...

BN ImmunoTherapeutics Announces Partnership With National Cancer Institute.
August 25, 2008... BN ImmunoTherapeutics, Inc. has entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and BN ImmunoTherapeutics will jointly...

MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research.
August 25, 2008... MabVax Therapeutics, Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, announced the completion of two separate...